GlassScriptPhysician profile
William D Rheuble
NPI 1326120353
$1,453.06
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.78 · 2020: $407 · 2021: $393 · 2022: $387 · 2023: $162 · 2024: $43.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $334.99 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $175.57 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $155.27 | 2020 | |
| Lilly USA, LLC | $147.48 | 2020-2023 | Emgality, Jardiance |
| Amgen INC. | $99.40 | 2022 | |
| Novo Nordisk INC | $95.00 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $90.68 | 2021-2023 | Farxiga, Breztri |
| Pfizer INC. | $60.63 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $40.09 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.60 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.75 | 2022 | |
| Allergan, INC. | $26.20 | 2019-2020 | |
| Eisai INC. | $23.80 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.66 | 2022 | |
| Tris Pharma INC | $19.02 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18.96 | 2022 | |
| Astellas Pharma US INC | $16.39 | 2024 | Veozah |
| Shire North American Group INC | $15.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.99 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.91 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.93 | 2023 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $12.50 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rheuble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.